Literature DB >> 1454765

[A program for medical use of information systems. Validity of calculation of direct costs for the initial treatment of acute myeloblastic leukemia].

J P Marie1, S Bisserbe, C Bouaziz, T Wdowick, R Zittoun.   

Abstract

In order to validate the information systems medicalization program used since 1984 at the Hôtel-Dieu hospital, Paris, the direct costs given by this program were compared with those calculated from the medical records of 10 adult patients hospitalized for diagnosis and treatment of acute myeloblastic leukaemia. The mean direct cost of an 8 to 81 days hospital stay was estimated at 75.393 +/- 41.260 French francs by the program and 84.969 +/- 52.288 FF by calculations from the records. A fairly good correlation (r2 = 0.72; P = 0.002) was found between the 2 evaluations. There was no statistically significant difference between the figures obtained by the 2 methods, except for pharmaceutical expenditures (P = 0.005) which were grossly underevaluated by the program. A better correlation could be obtained if an attribution of drugs and transfusions per patient was entered in the program.

Entities:  

Mesh:

Year:  1992        PMID: 1454765

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Induction-related cost of patients with acute myeloid leukaemia in France.

Authors:  Virginie Nerich; Bruno Lioure; Maryline Rave; Christian Recher; Arnaud Pigneux; Brigitte Witz; Martine Escoffre-Barbe; Marie-Pierre Moles; Eric Jourdan; Jean Yves Cahn; Marie-Christine Woronoff-Lemsi
Journal:  Int J Clin Pharm       Date:  2011-01-28

Review 2.  Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.

Authors:  Roland B Walter; Lenise R Taylor; Kelda M Gardner; Kathleen Shannon Dorcy; Jennifer E Vaughn; Elihu H Estey
Journal:  Clin Adv Hematol Oncol       Date:  2013

3.  Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma.

Authors:  Philippe Fagnoni; Noel Milpied; Samuel Limat; Eric Deconinck; Virginie Nerich; Charles Foussard; Philippe Colombat; Jean-Luc Harousseau; Marie-Christine Woronoff-Lemsi
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.558

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.